cyrilzakka/clinical-trials huggingface dataset:
Parkinson's Disease and Gamma-transcranial Alternating Current Stimulation

Cortical-basal ganglia gamma oscillations are pathologically reduced in Parkinson's disease (PD) and the plasticity of the primary motor cortex (M1) is impaired. Enhancing gamma oscillations through transcranial alternating current stimulation (tACS), a non-invasive neurophysiological tool that modulates cortical rhythms, can restore this alteration. However, whether tACS-related normalization of M1 plasticity results in positive clinical effects is unknown. Motor learning is also impaired in PD and gamma oscillations play a relevant role in different forms of learning in humans. Nevertheless, whether motor learning abnormalities relate to reduced gamma oscillations in PD is another unclear issue. It can be hypothesized that gamma oscillations impairment in M1 contributes to altered motor control, plasticity and learning in PD. Accordingly, in this project, the authors intend to test whether gamma-tACS on M1 in PD patients ameliorates motor performance and learning, as objectively assessed with kinematic techniques.


Eligibility Criteria:
Inclusion Criteria:

* PD diagnosis

Exclusion Criteria:

* severe cognitive and psychiatric comorbidities
* H\&Y\>3
* levodopa-induced dyskinesia and tremor-dominant phenotype
* history of additional neuropsychiatric disorders
* intake of medications acting on brain excitability or plasticity
* contraindications to non-invasive brain stimulation
Learning Curve of VL for Intubation During CPR

This is a clinical study based on analysis of video-clip data of endotracheal intubation (ETI) using videolaryngoscope (VL) and clinical data for cardiopulmonary resuscitation patients between 2012.03.01.-2015.02.28.

The purpose of this study is to evaluate the appropriate numbers of VL usages for successful ETI at first attempt during cardiopulmonary resuscitation.

Direct layngoscope (DL) is a basic tool for endotracheal intubation(ETI) during cardiopulmonary resuscitation(CPR). ETI during CPR has higher risks of failure or delayed success with frequent attempts, misplacement of the tube, and prolonged interruptions of chest compressions. The main problems associated with ETI relate to the inherently technical difficulty in using DL. VL have various advantages of fast learning curve and overall success comparing with the DL in non-arrest patients, but there was no known data of learnig curve of successful ETI during CPR.

This study tried to estimate the the appropriate numbers of VL usage for successful ETI at first attempt during CPR. So the investigators analyze the success rate, speed, trial number, incidence of complications, and hands-off time of ETI using VL which in real clinical setting. In addition, this study analyze the residency training term, total number of of VL usage using VL at that time.

Eligibility Criteria:
Inclusion Criteria:

* patients who suffer sudden cardiac arrest and physician tried ti intubate using viseolaryngoscope.

Exclusion Criteria:

* case of requesting the do-not-attempt resuscitation befor ETI
* intubated cases before arrival to emergency department
* physician tried ti intubate using direct-laryngoscope
Allogeneic Mesenchymal Stem Cells for the Critical Limb Ischemia Therapy

The clinical trial aims to study the safety and efficacy of adult allogeneic mesenchymal stem cells for the treatment of critical limb ischemia.


Eligibility Criteria:
Inclusion Criteria:

1. Males or females in the age group of 18-80 yrs of Caucasian origin.
2. Peripheral artery disease (PAD) against the background of atherosclerosis and diabetes mellitus (DM)
3. Critical lower limb ischemia (stages 3-4 by Fontaine-Pokrovsky or stages 4-6 by Rutherford)
4. Patients with remaining symptoms of critical limb ischemia (CLI) in spite of the performed surgical (endovascular or open) treatment and continuing conservative therapy
5. Patients with absent emergency indications to major amputation
6. Patients planned for the reconstructive surgery with a questionable remote outcome due to compromised blood outflow
7. Ankle Brachial Pressure Index (ABPI) ≤ 0.5 or ankle pressure ≤ 70 mm Hg
8. Patients, if having associated Type II Diabetes, should be on medication and well controlled (HbA1c ≤ 8.5 %)
9. On regular medication for hypertension if needed
10. Normal liver and renal function (or having clinically insignificant deviations, according to the treating physician's opinion)
11. Patients who are able to understand the requirements of the study, and willing to provide voluntary written informed consent, abide by the study requirements, and agree to return for required follow-up visits

Exclusion Criteria:

1. Humid gangrene or acute/chronic infection of lower limb.
2. Dry gangrene with extensive foot lesion (\> 1\\2).
3. Acute arterial failure.
4. Life-threatening conditions and predicted life expectancy of \< 6 months.
5. Presence of neoplasm or bone marrow disease
6. Signs of active or chronic, including latent, haemorrhage
7. Any acute or chronic infectious disease
8. Renal failure determined as twofold or higher elevation of serum creatinine as compared to the upper normal limit
9. Hepatic failure determined as the bilirubin, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels elevated by two and more times over the upper normal limits
10. Thrombocytopenia (platelet counts \< 50,000 /µl), leukocytopenia (WBC \< 4,000/µl), immunosuppressive therapy
11. Pronounced neurological deficit
12. Patients with gait disturbance for reasons other than CLI
13. Patients not suitable for cell therapy, by the treating physician's opinion
14. CLI patients requiring amputation at the proximal to the trans-metatarsal level
15. Patients with Type I diabetes
16. Patients having respiratory complications/left ventricular ejection fraction \< 25%
17. Stroke or myocardial infarction within last 3 months
18. Patients who are contraindicated for X-ray angiography
19. History of severe alcohol or drug abuse within 3 months of screening
20. Pregnant and lactating women.
21. Patients tested positive for HIV 1, hepatitis C virus (HCV), hepatitis B virus (HBV)
22. Unsigned informed consent
Enbrel® in Psoriatic Arthritis

This study is testing the effect of etanercept in treating both the skin and joint symptoms of psoriatic arthritis patients. Enbrel®, also known as etanercept, has already been approved by the Federal Food Drug Administration for the treatment of psoriatic arthritis. It is taken as an injection under the skin. Participants in the trial will be offered etanercept free of charge to be self-injected once weekly for 24 weeks. During that period they will have 5 appointments at the study center and will also be asked to complete assessments of their health.


Eligibility Criteria:
Individuals may be eligible to enroll in this study if they suffer from psoriasis (covering at least 10% of the body), and: - have had two or more swollen, tender or painful joints for at least 3 months or: - have lower back pain which your physician has diagnosed as sacroiliitis or spondylitis in one or more joints or: - have been diagnosed with active psoriatic arthritis
Envision® Surface Evaluation

This observational study will acquire initial clinical practice utilization and product safety data for the Envision® surface.

This is a single site, open label, observational study to acquire initial clinical practice utilization information, product safety, and wound healing data, as defined by changes in wound volume and/or surface area, for patients with pressure ulcers placed on this surface.

Eligibility Criteria:
Inclusion Criteria:

* Subject Weight \< 400 lbs. Subject has Stage II, III, or IV pressure ulcer on weight bearing aspect of the body Subject estimated length of stay at least 7 days Subject Ability to provide informed consent

Exclusion Criteria:

* Inability to provide informed consent
Recombinant Human Interferon a-2b Gel for HPV Gynecological Infections

to assess the efficacy and safety of recombinant human interferon α-2b gel (Yallaferon®) for the treatment of patients with cervical high-risk HPV infections; to analyze the HPV type infections and clinical negative conversion.

285 patients with positive high risk HPV infection were randomized into interferon gel group and control group at ratio of 2:1 (203 patients in treatment group and 82 patients in control group). The patients in treatment group received 1g recombinant human α-2b interferon gel every other day for consecutive 3 courses of treatment, whereas no treatment was conducted in control group.


Eligibility Criteria:
Inclusion Criteria:

1. Age 30 to 65 years of age the sex life of female patients;
2. , liquid-based cytology (TCT) check no intraepithelial lesions and malignant cells;
3. , HPV DNA typing test for high-risk HPV positive (including a single high-risk type positive, and more high-risk type of positive and high-and low-risk hybrid positive).

15 kinds of high-risk types, including HPV16, 18,31,33,35,39,45,51,52,53,56,58,59,66,68

Exclusion Criteria:

* (1) cervical intraepithelial neoplasia (CIN); (2), combined with a severe fungal, trichomonas vaginitis; (3), severe primary diseases associated with cardiovascular, liver, kidney and hematopoietic system; (4), allergies or allergy to the drug known ingredients. (5), within 30 days to accept other clinical trials of drugs or are participating in clinical trials; (6), pregnant and lactating women and to be pregnant women; (7), the researchers do not consider it appropriate clinical trials.
Smart-CKD/BP Study

Through remote management and propaganda of intelligent mobile phone, the standard rate of blood pressure control and the change of renal function were observed.


Eligibility Criteria:
Inclusion Criteria:

1. diagnosis in line with the 2012 international kidney disease: improving global outcomes (kidney disease improving global out-comes, KDIGO) of chronic kidney disease diagnosis standard of hypertension diagnosis, "China Hypertension Prevention Guide 2010" diagnostic criteria;
2. and will have the use of intelligent mobile phone, and a network connection;
3. at the age of 18-70.

Exclusion Criteria:

1. GFR\<15 ml/min or start replacement therapy;
2. do not understand Chinese, do not understand Chinese;
3. malignant tumor patients;
4. have mental illness;
5. there is consciousness disorder.
An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018

This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.

Patients with Parkinson's disease with motor complications on levodopa therapy who completed the prior double-blind studies 6002-EU-007, 6002-US-013 or 6002-US-018 are eligible to enter into this 1-year, long-term open safety study with a starting istradefylline dose of 40mg per day.

Eligibility Criteria:
Inclusion Criteria:

* Completion of study 6002-EU-007, 6002-US-013 or 6002-US-018
* Non-pregnant and either not of childbearing potential or using specified contraception

Exclusion Criteria:

* History of psychotic illness
* Variant/atypical Parkinson's disease
* Cancer within 5 years of enrollment
* ALT/AST levels \> 1.5 times ULN
* Seizure disorder
* Neuroleptic malignant syndrome
Effectiveness of a CBT-based mHealth Intervention Targeting MOUD Retention, Adherence, and Opioid Use

The focus of this study is to examine the effectiveness of imFREE relative to mHealth ED in facilitating treatment retention and adherence and reducing opioid use among adults with OUD initiating BUP treatment.

There are two specific aims: (1) to test the effectiveness of imFREE, delivered in conjunction with medical management with buprenorphine (imFREE + MM), relative to mHealth ED + MM, in facilitating buprenorphine treatment retention and adherence in a population of individuals with OUD initiating MM (N=200). (2) To evaluate the cost-effectiveness of imFREE.


Eligibility Criteria:
Inclusion Criteria:

* Age \> 18
* DSM-5 diagnosis of OUD
* no more than 2 weeks from the date of BUP induction
* able to read and comprehend English at the 6th grade level (determined by REALM)
* able to provide informed consent
* presently owns a mobile phone that can send and receive text messages

EXCLUSION CRITERIA

Participants must not have:

1. Life threatening or unstable medical illness requiring treatment or making participation difficult
2. Dependence on alcohol or other illicit substances for which medical detoxification is imminently needed
3. Presence of acute psychiatric symptoms warranting intensive treatment or hospitalization (e.g., acute suicidality or mania).
TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients

The purpose of this study is to determine the effectiveness, safety, and tolerability (how well the body stands the drug) of an investigational protease inhibitor (PI) called TMC114 given with low dose ritonavir.

A phase II randomized, controlled, partially blinded, trial to investigate dose response of TMC114/RTV in HIV-1 infected patients who have previously received all three licensed classes of HIV antiviral drugs (known as nucleoside reverse transcriptase inhibitors (NRTI), nonnucleoside reverse transcriptase inhibitors (NNRTI) and protease inhibitors (PI)), and who are on a stable PI-containing regimen not including an NNRTI may be eligible to participate. Four doses of TMC-114/ritonavir will be studied. 300 patients in the United States and Puerto Rico will participate. The duration of the study is 96 weeks. Randomize to one of 4 treatment groups (TMC114/RTV: 400/100 mg qd; 800/100mg qd; 400/100mg bid; 600/100 bid) or control arm for 24 to 48 wks. Optimal dose (TMC114/RTV 600/100mg bid) open label portion of the study. The trial was extended to include 144Wks of treatment.

Eligibility Criteria:
Inclusion Criteria:

* Male or female, age 18 years or older
* Documented HIV-1 infection
* Stable PI regimen for at least 8 weeks prior to screening
* Plasma viral load at screening above 1000 HIV-1 RNA copies/ml
* Prior use of more than 1 NRTI for at least 3 months
* Prior use of one or more NNRTIs as part of a failing regimen
* At least 1 primary PI mutation as defined by the IAS guidelines
* Treatment with at least 1 PI for a total of at least 3 months
* Patient has given informed consent

Exclusion Criteria:

* Presence of any currently active AIDS defining illness except stable cutaneous Kaposi's Sarcoma and Wasting syndrome due to HIV infection
* Current or past history of alcohol and/or drug abuse which, in the investigator's opinion, would compromise the subject's safety or compliance to the study protocol procedures
* NNRTI as part of therapy at screening
* Patients on a treatment interruption at screening
* Patients for whom an investigational antiretroviral therapy is part of the regimen at screening or the use of any non-antiretroviral investigational agents 90 days prior to screening
* Hepatitis A, B, or C.
SAM: Discharge Based on the Use of a MUAC-based Criterion to

Retrospective analysis of routine program data of children aged 6 to 59 months admitted to the MSF therapeutic feeding program with MUAC ≤ 118 mm in Yako and Titao districts of Burkina Faso from 2007-2011.

Comparison of patient characteristics and treatment outcomes was conducted between two groups: 1) children discharged as recovered from September 2007 to March 2009 with at least 15% of their weight at admission (Period A); and 2) children discharged as recovered from April 2009 to December 2011 with MUAC ≥ 124 mm (Period B).

A total of 50,841 children were admitted with MUAC ≤ 118 mm to the MSF therapeutic feeding program and were included in this analysis: 24,792 children in Period A (2007-2009) and 26,049 children in Period B (2009-2011).

Overall, 89% of admissions were directly into outpatient care and the majority (53%) entered with a MUAC 116-118mm; 48% of children were male and 80% of children \< 2 years of age (Table 1).

Compared to children admitted in Period A, children admitted in Period B were statistically more likely to be female, younger, and of better anthropometric status (e.g. higher mean MUAC, WHZ and HAZ).

There was a greater proportion of children admitted directly to inpatient care in Period B than in Period A (10.6% vs 8.0%).

Eligibility Criteria:
Inclusion Criteria:

* 6 to 59 months old
* presence of bipedal pitting edema or MUAC ≤ 118 mm

Exclusion Criteria:

* \< 6 months old or \> 59 months old
* absence of bipedal pitting edema or MUAC ≥ 118 mm
Transcranial Direct Current Stimulation (tDCS) as Therapeutical Strategy for Negative Symptoms in Schizophrenia

The current research is aimed at using Transcranial Direct Current Stimulation (tDCS) as complementary therapeutic tool in the treatment of schizophrenia. Patients will be randomized into two groups (tDCS-active x tDCS-sham) accordingly to detailed protocol. Main outcome will be measured by specific clinical rating scales based on the assessment of negative symptoms. A total of 40 patients ought to be enrolled as specified in methodology. Secondary outcomes shall include collateral effects evaluation, anxiety and depressive scales as well as clinical monitoring.

Overview

The present study is a double-blind randomized clinical trial in which patients should be allocated from a General Psychiatry Service into two groups (tDCS-active x tDCS-sham). Subjects who fulfilled eligibility criteria will undergo ten days of consecutive stimulation (active or sham) and will return after two to four weeks for final clinical assessment. Patients who shown no response in rating scales and that were allocated to sham intervention group will be able to choose whether or not they want to undergo the active intervention at follow up (partial cross-over)

Eligibility Criteria:
Inclusion Criteria:

* patients with age between 18-59 years
* diagnostic of Schizophrenia or Schizoaffective Disorder as stated by DSM-IV and confirmed by SCID (Structured Clinical Interview for DSMIV), to be tested by a psychiatrist
* baseline score higher than 20 for negative symptoms at PAAN
* patients able to read and understand Portuguese.

Exclusion Criteria:

* other psychiatric diagnosis
* criteria for bipolar disorder; dementia; other psychotic disturbs; substance related disorders
* presence of other severe neurological or clinical diseases
* presence of suicidal behavior (planning or attempt in the previous 4 weeks)
* pregnancy
* incapacity of coping with the informed consent
* specific tDCS limitations (such as anatomic problems)

Regarding medication: all patients should have stable dosology of medications for at least 6 weeks
Effects of Additional Functional Strength Training on Mobility in Children With Hemiplegic Cerebral Palsy

The randomized control trail was to determine the effects of additional functional Strength Training on mobility in Children with Hemiplegic Cerebral Palsy.

The aim of functional physiotherapy is to train the child by emphasizing him to learn motor abilities. These motor abilities are those that are thought to be though either by children with cerebral palsy or their parents. Functional activities are learned by the repetitive practice of goal-oriented tasks in a given functional situation. This approach instead of focusing on normality, it focuses on functionality. In this way, it is very necessary for the child to practice a given task functionally rather than normally.No studies have been done to improve mobility and strength in lower limb in children with hemiplegia cerebral palsy. So for this reason, this study is conducted to investigate the effects of additional functional Strength Training on mobility in Children with Hemiplegic Cerebral Palsy.In this way we can make these children an active participant of the society.

Eligibility Criteria:
Inclusion Criteria:

children who didnot use the assistive device children who follow the commands children who did not treated in any other rehabilitation center

Exclusion Criteria:

children with any other diagnosis other than CP children with fixed contractures children underwent surgery children who received Botulinum Toxin
Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm

This is a Phase II pilot exploratory study designed to investigate if prophylactic treatment with short term steroids administered to high risk Covid-19 patient might prevent cytokine storm and progression to respiratory failure. High risk is defined based on serologic markers of inflammation that include abnormalities of Interleukin 6 (IL-6), Ferritin , D-dimer, Lactate Dehydrogenase (LDH), as well as lymphopenia and impaired O2 saturation prior to or on the 7th day of first symptom of Covid-19.

To decrease the rate of progression to hypoxemic respiratory failure in high risk patients with Covid-19, treated with prophylactic steroids during the first phase of the disease.

Eligibility Criteria:
Inclusion Criteria:

* All patients diagnosed with Covid-19 will be registered on the study regardless pf their severity, but only those who meet high risk criteria will be treated with steroids. Those who don't meet the criteria will only be registered with no need to collect further data except baseline labs and CT Chest. They should sign the consent form and the data manager can collect the rest of the information.
* Patients older than 18 years diagnosed with Covid-19 by Polymerase Chain Reaction (PCR) or by rapid serological test will be eligible. Cases who are Immunoglobulin G (IgG) positive but Immunoglobulin M (IgM) negative, will not be considered eligible unless they are positive for molecular PCR test. Eligible patients will be registered on study on or before 7 days from first onset of symptoms.

Exclusion Criteria:

* Any patient with life expectancy \< 1 month
* Any patient who is oxygen dependent
* Any patient with long standing history of severe Chronic Obstructive Pulmonary Disease (COPD)
* Any patient who is chronically oxygen dependent because of previous existing lung disease
* Anyone with severely uncontrolled diabetes despite adequate management
* Anyone with active serious bacterial infection such as septicemia or pneumonia
* Anyone receiving Tocilizumab (anti IL-6 therapy) or plasma therapy
* Any patient already receiving steroids from another pre-existing illness